arrow
G

Gianpaolo Vidili

azienda ospedaliero
H指数:16
被引数:1,196

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcome of hepatic resection for HCC in ideal and non-ideal candidates

理想和非理想候选者行肝切除治疗HCC的结局

2025-07-290
OA
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study

根据IMbrave050标准,肝细胞癌根治性切除或消融后的复发率、特征及结局:一项真实世界研究

2025-06-260
OA
Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma

系统性炎症反应标志物提高了肝细胞癌预后模型的鉴别能力

2025-03-251
OA
Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma

丙型肝炎病毒复制缺失与抗HCV阳性肝细胞癌患者预后改善相关

2025-01-080
OAAI
HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma
2024-09-060
OAAI
Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care

索拉非尼和节律性卡培他滨在Child-Pugh B级晚期肝癌患者中的应用: 与最佳支持治疗的现实比较

2024-09-014
PRE
Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma
2024-03-012
OAAI
Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection

一线肝切除术治疗的肝细胞癌患者不可移植复发的预测因素

2023-09-277
OAAI
Outcomes of Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced hepatocellular carcinoma in the era of immunotherapy: A real-life comparison with best supportive care
2023-09-010
PRE
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs
2023-08-016
OAAI
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors
2022-11-0113
PRE
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma
2022-09-016
PRE
Surveillance for hepatocellular carcinoma with a 3-months interval in extremely high-risk patients does not further improve survival

对极高危患者进行3个月间隔的肝细胞癌监测并不能进一步提高生存率

2022-07-014
PRE
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment
2022-01-318
OAAI